Literature DB >> 17101166

Mutations in the V3 stem versus the V3 crown and C4 region have different effects on the binding and fusion steps of human immunodeficiency virus type 1 gp120 interaction with the CCR5 coreceptor.

Pirada Suphaphiphat1, Max Essex, Tun-Hou Lee.   

Abstract

The current model for HIV-1 envelope-coreceptor interaction depicts the V3 stem and bridging sheet binding to the CCR5 N-terminus while the V3 crown interacts with the second extracellular loop, which is the coreceptor domain that appears to be relatively more important for fusion and infection. Our prediction based on this model is that mutations in the V3 crown might consequently have more effects on cell-cell fusion and virus entry than mutations introduced in the V3 stem and C4 region. We performed alanine-scanning of the V3 loop and selected C4 residues in the JRFL envelope and tested the capacity of the resulting mutants for CCR5 binding, cell-cell fusion, and virus infection. Our cross comparison analysis revealed that residues in C4 and in both the V3 stem and crown were important for CCR5 binding of gp120 subunits. Contrary to our prediction, mutations in the V3 crown had less effect on membrane fusion than mutations in the V3 stem. The V3 stem thus appears to be the most important region for CCR5 utilization since it affected both coreceptor binding and subsequent fusion and viral entry. Our data raises the possibility that some residues in the V3 crown and in C4 may play distinct roles in the binding and fusion steps of envelope-coreceptor interaction.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17101166      PMCID: PMC2014721          DOI: 10.1016/j.virol.2006.10.019

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  25 in total

1.  Fine definition of a conserved CCR5-binding region on the human immunodeficiency virus type 1 glycoprotein 120.

Authors:  C Rizzuto; J Sodroski
Journal:  AIDS Res Hum Retroviruses       Date:  2000-05-20       Impact factor: 2.205

2.  Mapping the determinants of the CCR5 amino-terminal sulfopeptide interaction with soluble human immunodeficiency virus type 1 gp120-CD4 complexes.

Authors:  E G Cormier; D N Tran; L Yukhayeva; W C Olson; T Dragic
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

3.  Development of a cell-based enzyme-linked immunosorbent assay for high-throughput screening of HIV type 1 entry inhibitors targeting the coreceptor CXCR4.

Authors:  Qian Zhao; Hong Lu; Dominique Schols; Erik De Clercq; Shibo Jiang
Journal:  AIDS Res Hum Retroviruses       Date:  2003-11       Impact factor: 2.205

4.  Structure of a V3-containing HIV-1 gp120 core.

Authors:  Chih-chin Huang; Min Tang; Mei-Yun Zhang; Shahzad Majeed; Elizabeth Montabana; Robyn L Stanfield; Dimiter S Dimitrov; Bette Korber; Joseph Sodroski; Ian A Wilson; Richard Wyatt; Peter D Kwong
Journal:  Science       Date:  2005-11-11       Impact factor: 47.728

5.  Simple methods for monitoring HIV-1 and HIV-2 gp120 binding to soluble CD4 by enzyme-linked immunosorbent assay: HIV-2 has a 25-fold lower affinity than HIV-1 for soluble CD4.

Authors:  J P Moore
Journal:  AIDS       Date:  1990-04       Impact factor: 4.177

6.  Site-directed mutagenesis by overlap extension using the polymerase chain reaction.

Authors:  S N Ho; H D Hunt; R M Horton; J K Pullen; L R Pease
Journal:  Gene       Date:  1989-04-15       Impact factor: 3.688

7.  Effect of amino acid substitution of the V3 and bridging sheet residues in human immunodeficiency virus type 1 subtype C gp120 on CCR5 utilization.

Authors:  Pirada Suphaphiphat; Arunee Thitithanyanont; Saowakon Paca-Uccaralertkun; Max Essex; Tun-Hou Lee
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

8.  The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor.

Authors:  Emmanuel G Cormier; Tatjana Dragic
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

9.  Impact of mutations in the coreceptor binding site on human immunodeficiency virus type 1 fusion, infection, and entry inhibitor sensitivity.

Authors:  Jacqueline D Reeves; John L Miamidian; Mark J Biscone; Fang-Hua Lee; Navid Ahmad; Theodore C Pierson; Robert W Doms
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

Review 10.  HIV-1 gp41: mediator of fusion and target for inhibition.

Authors:  Carol D Weiss
Journal:  AIDS Rev       Date:  2003 Oct-Dec       Impact factor: 2.500

View more
  19 in total

1.  Conserved determinants of enhanced CCR5 binding in the human immunodeficiency virus subtype D envelope third variable loop.

Authors:  Samaporn Teeravechyan; M Essex; Tun-Hou Lee
Journal:  AIDS Res Hum Retroviruses       Date:  2010-04       Impact factor: 2.205

2.  A Prominent Site of Antibody Vulnerability on HIV Envelope Incorporates a Motif Associated with CCR5 Binding and Its Camouflaging Glycans.

Authors:  Devin Sok; Matthias Pauthner; Bryan Briney; Jeong Hyun Lee; Karen L Saye-Francisco; Jessica Hsueh; Alejandra Ramos; Khoa M Le; Meaghan Jones; Joseph G Jardine; Raiza Bastidas; Anita Sarkar; Chi-Hui Liang; Sachin S Shivatare; Chung-Yi Wu; William R Schief; Chi-Huey Wong; Ian A Wilson; Andrew B Ward; Jiang Zhu; Pascal Poignard; Dennis R Burton
Journal:  Immunity       Date:  2016-07-19       Impact factor: 31.745

3.  Analysis of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis.

Authors:  Ralph Pantophlet; Rowena O Aguilar-Sino; Terri Wrin; Lisa A Cavacini; Dennis R Burton
Journal:  Virology       Date:  2007-04-06       Impact factor: 3.616

Review 4.  Bioinformatic analysis of HIV-1 entry and pathogenesis.

Authors:  Benjamas Aiamkitsumrit; Will Dampier; Gregory Antell; Nina Rivera; Julio Martin-Garcia; Vanessa Pirrone; Michael R Nonnemacher; Brian Wigdahl
Journal:  Curr HIV Res       Date:  2014       Impact factor: 1.581

5.  An altered and more efficient mechanism of CCR5 engagement contributes to macrophage tropism of CCR5-using HIV-1 envelopes.

Authors:  Jasminka Sterjovski; Michael Roche; Melissa J Churchill; Anne Ellett; William Farrugia; Lachlan R Gray; Daniel Cowley; Pantelis Poumbourios; Benhur Lee; Steven L Wesselingh; Anthony L Cunningham; Paul A Ramsland; Paul R Gorry
Journal:  Virology       Date:  2010-06-08       Impact factor: 3.616

6.  R5X4 viruses are evolutionary, functional, and antigenic intermediates in the pathway of a simian-human immunodeficiency virus coreceptor switch.

Authors:  Silvana Tasca; Siu-Hong Ho; Cecilia Cheng-Mayer
Journal:  J Virol       Date:  2008-05-14       Impact factor: 5.103

7.  Structure-Based Design of a Small Molecule CD4-Antagonist with Broad Spectrum Anti-HIV-1 Activity.

Authors:  Francesca Curreli; Young Do Kwon; Hongtao Zhang; Daniel Scacalossi; Dmitry S Belov; Artur A Tikhonov; Ivan A Andreev; Andrea Altieri; Alexander V Kurkin; Peter D Kwong; Asim K Debnath
Journal:  J Med Chem       Date:  2015-08-28       Impact factor: 7.446

Review 8.  Tropism testing in the clinical management of HIV-1 infection.

Authors:  Nina H Lin; Daniel R Kuritzkes
Journal:  Curr Opin HIV AIDS       Date:  2009-11       Impact factor: 4.283

9.  Env sequence determinants in CXCR4-using human immunodeficiency virus type-1 subtype C.

Authors:  Nina H Lin; Carlos Becerril; Francoise Giguel; Vladimir Novitsky; Sikhulile Moyo; Joseph Makhema; Myron Essex; Shahin Lockman; Daniel R Kuritzkes; Manish Sagar
Journal:  Virology       Date:  2012-09-03       Impact factor: 3.616

10.  Selected amino acid mutations in HIV-1 B subtype gp41 are associated with specific gp120v₃ signatures in the regulation of co-receptor usage.

Authors:  Salvatore Dimonte; Fabio Mercurio; Valentina Svicher; Roberta D'Arrigo; Carlo-Federico Perno; Francesca Ceccherini-Silberstein
Journal:  Retrovirology       Date:  2011-05-12       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.